Literature DB >> 22564133

Bevacizumab in ovarian cancer: unanswered questions.

Franco Muggia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22564133     DOI： 10.2165/11633510-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  15 in total

1.  Ovarian cancer: breaking the silence.

Authors: 
Journal:  Lancet Oncol       Date:  2012-02       Impact factor: 41.316

2.  BRCA genes: lessons learned from experimental and clinical cancer.

Authors:  F Muggia; T Safra; L Dubeau
Journal:  Ann Oncol       Date:  2011-01       Impact factor: 32.976

3.  Challenges and pitfalls of combining targeted agents in phase I studies.

Authors:  Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

Review 6.  Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Authors:  Rebecca L Stone; Anil K Sood; Robert L Coleman
Journal:  Lancet Oncol       Date:  2010-03-10       Impact factor: 41.316

Review 7.  Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

8.  Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Authors:  Dhaval K Shah; Beom Soo Shin; Jean Veith; Karoly Tóth; Ralph J Bernacki; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2009-02-20       Impact factor: 4.030

9.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 10.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675
View more
  1 in total

1.  Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.

Authors:  Congyan Shu; Pengyan Sun; Hanghang Xie; Weiwei Huang; Jialong Qi; Yanbing Ma
Journal:  Int J Nanomedicine       Date:  2020-03-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.